Comparison of irisin hormone expression between thyroid cancer tissues and oncocytic variant cells

ArticleAçık Erişim

Özet

Objective: The incidence of thyroid cancer has been continuously increasing. The main objective of this study was to investigate irisin expression in various thyroid pathologies and to compare these expression patterns with irisin expression in healthy thyroid tissues. Methods: The study groups consisted of 20 cases each of control thyroid tissue, Hashimoto’s thyroiditis, thyroid papillary carcinoma, oncocytic papillary carcinoma, follicular thyroid carcinoma, oncocytic follicular thyroid carcinoma, medullary thyroid carcinoma, anaplastic thyroid carcinoma. Irisin expression was evaluated using immunohistochemistry. Irisin levels in thyroid tissue supernatants were measured using ELISA. Results: Patients with HT showed increased irisin expression compared with controls (p<0.05). In addition, mild immunoreactivity was observed in the thyroid tissues of patients with papillary carcinoma while significantly increased irisin immunoreactivity was observed tissues of patients with oncocytic papillary carcinoma (p<0.05). There was no difference in irisin immunoreactivity in thyroid tissues between patients with follicular carcinoma and controls. However, irisin immunoreactivity was higher in tissues of patients with oncocytic follicular carcinoma than in tissues of patients with follicular carcinoma (p<0.05). No irisin immunoreactivity was observed in tissues of patients with medullary carcinoma, a malignant tumor the thyroid; however, irisin expression was significantly increased in tissues of patients with anaplastic carcinoma compared with that in tissues of controls (p<0.05). Furthermore, in all thyroid tissues with irisin expression, irisin immunoreactivity was observed in follicular cells, indicating that irisin is produced by these cells. Conclusion: Irisin is a novel potential immunohistochemical marker for differentiating oncocytic variants of papillary and FTCs from papillary and follicular thyroid cancers. © 2019 Ugur et al.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/14161Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.2147/cmar.s201979Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorUgur, Kader
dc.contributor.authorAydin, Suleyman
dc.contributor.authorKuloglu, Tuncay
dc.contributor.authorArtas, Gokhan
dc.contributor.authorKocdor, Mehmet Ali
dc.contributor.authorSahin, Ibrahim
dc.contributor.authorYardim, Meltem
dc.contributor.authorOzercan, Ibrahim Hanefi
dc.date.accessioned2026-10-18T20:28:56.814120691Z
dc.date.available2026-10-18T20:28:56.814120691Z
dc.date.issued2019
dc.description.abstractObjective: The incidence of thyroid cancer has been continuously increasing. The main objective of this study was to investigate irisin expression in various thyroid pathologies and to compare these expression patterns with irisin expression in healthy thyroid tissues. Methods: The study groups consisted of 20 cases each of control thyroid tissue, Hashimoto’s thyroiditis, thyroid papillary carcinoma, oncocytic papillary carcinoma, follicular thyroid carcinoma, oncocytic follicular thyroid carcinoma, medullary thyroid carcinoma, anaplastic thyroid carcinoma. Irisin expression was evaluated using immunohistochemistry. Irisin levels in thyroid tissue supernatants were measured using ELISA. Results: Patients with HT showed increased irisin expression compared with controls (p<0.05). In addition, mild immunoreactivity was observed in the thyroid tissues of patients with papillary carcinoma while significantly increased irisin immunoreactivity was observed tissues of patients with oncocytic papillary carcinoma (p<0.05). There was no difference in irisin immunoreactivity in thyroid tissues between patients with follicular carcinoma and controls. However, irisin immunoreactivity was higher in tissues of patients with oncocytic follicular carcinoma than in tissues of patients with follicular carcinoma (p<0.05). No irisin immunoreactivity was observed in tissues of patients with medullary carcinoma, a malignant tumor the thyroid; however, irisin expression was significantly increased in tissues of patients with anaplastic carcinoma compared with that in tissues of controls (p<0.05). Furthermore, in all thyroid tissues with irisin expression, irisin immunoreactivity was observed in follicular cells, indicating that irisin is produced by these cells. Conclusion: Irisin is a novel potential immunohistochemical marker for differentiating oncocytic variants of papillary and FTCs from papillary and follicular thyroid cancers. © 2019 Ugur et al.
dc.identifier.doi10.2147/cmar.s201979
dc.identifier.endpage2603
dc.identifier.issn1179-1322
dc.identifier.pmcidPMC6497896
dc.identifier.pmid31114326
dc.identifier.scopus2-s2.0-85065215161
dc.identifier.startpage2595
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/14161
dc.identifier.volume11
dc.identifier.wosWOS:000463245400001
dc.language.isoen
dc.publisherDove Medical Press Ltd
dc.relation.ispartofCancer Management and Research
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectDiagnostic biomarker
dc.subjectImmunohistochemistry
dc.subjectIrisin
dc.subjectThyroid cancer
dc.subjectanaplastic thyroid carcinoma
dc.subjectArticle
dc.subjectclinical article
dc.subjectcomparative study
dc.subjectcontrolled study
dc.subjectenzyme linked immunosorbent assay
dc.subjectfollicular thyroid carcinoma
dc.subjectHashimoto disease
dc.subjecthuman
dc.subjecthuman cell
dc.subjecthuman tissue
dc.subjectimmunoreactivity
dc.subjectoncocytic follicular thyroid carcinoma
dc.subjectoncocytic papillary carcinoma
dc.subjectprotein expression
dc.subjectthyroid carcinoma
dc.subjectthyroid medullary carcinoma
dc.subjectthyroid papillary carcinoma
dc.subjecttissue level
dc.titleComparison of irisin hormone expression between thyroid cancer tissues and oncocytic variant cells
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus19
rdl.citation.wos16
rdl.departmentDepartment of Medical Biology, School of Medicine, Erzincan Binali Yildirim University, Erzincan, Turkey.
rdl.oa.statusgold
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)